Comorbidities and cardiovascular risk factors in an aged cohort of HIV-infected patients on antiretroviral treatment in a Spanish hospital in 2016

References

• Chu C, Selwin P. An epidemic in evolution: the need for new models of HIV care in the chronic disease era. J Urb Health. 2011;88(3):556–566.
   PubMed Web of Science ®Google Scholar
• Hasse B, Ledergerber B, Furrer H, et al. Morbidity and aging in HIV-infected persons: the swiss HIV cohort study. Clin Infect Dis. 2011;53(11):1130–1139.
   PubMed Web of Science ®Google Scholar
• Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N Engl J Med. 1998;338(13):853–860.
   PubMed Web of Science ®Google Scholar
• Aberg JA, Gallant JE, Ghanem KG, et al. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the infectious diseases society of america. Clin Infect Dis. 2014;58(1):1–10.
   PubMed Web of Science ®Google Scholar
• Günthard HF, Saag MS, Benson CA, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the international antiviral society-USA panel. JAMA. 2016;316(2):191–210.
   PubMed Web of Science ®Google Scholar
• Katlama C, Valantin MA, Algarte-Genin M, et al. Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. AIDS. 2010;24(15):2365–2374.
   PubMed Web of Science ®Google Scholar
• Holtzman C, Armon A, Tedaldi E, et al. Polypharmacy and risk of antiretroviral drug interactions among the HIV-infected population. J Gen Intern Med. 2013;28(10):1302–1310.
   PubMed Web of Science ®Google Scholar
• Arribas JR, Girard PM, Landman R, et al. Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial. Lancet Infect Dis. 2015;15(7):785–792.
   PubMed Web of Science ®Google Scholar
• Lozano De León-Naranjo F. Envejecimiento prematuro y comorbilidades relacionadas con la edad en los pacientes con infección por el VIH. Revista Multidisciplinar Del Sida. 2014;1(3):18–32.
   Google Scholar
• Deeks SG. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med. 2011;62:141–155.
   PubMed Web of Science ®Google Scholar
• Schouten J, Wit FW, Stolte IG, et al. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV Cohort Study. Clin Infect Dis. 2014;59(12):1787–1797.
   PubMed Web of Science ®Google Scholar
• Grupo de expertos de la Secretaría del Plan Nacional sobre el sida (SPNS). Sociedad Española de Geriatría y Gerontología (SEGG). Madrid: Ministerio de Sanidad, Servicios Sociales e Igualdad; Noviembre 2015. Documento de consenso sobre edad avanzada e infección por el virus de la inmunodeficiencia humana. [ cited 2017 Dec 14]. Available from: https://www.msssi.gob.es/ciudadanos/enfLesiones/enfTransmisibles/sida/publicaciones/profSanitarios/docEdadAvanzadaVIH.pdf
   Google Scholar
• Kirchner JT. Clinical management considerations for dyslipidemia in HIV-infected individuals. Postgrad Med. 2012;124(1):31–40.
   PubMed Web of Science ®Google Scholar
• Bader MS, Kelly DV. Diagnosis and management of common chronic metabolic complications in HIV-infected patients. Postgrad Med. 2008;120(4):17–27.
   PubMed Web of Science ®Google Scholar
• Blanco JR, Jarrin I, Vallejo, et al. Definition advanced age HIV infection: looking age cut-off AIDS. Res Hum Retroviruses 2012;28(9):800–806.
   Web of Science ®Google Scholar
• Guaraldi G, Orlando G, Zona E, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis. 2011;53(11):1120–1126.
   PubMed Web of Science ®Google Scholar
• Smit M, Brinkman K, Geerlings S, et al. ATHENA observational cohort. Future challenges clinical care ageing population infected with HIV: modelling study. Lancet Infect Dis. 2015;15(7):810–818.
   PubMed Web of Science ®Google Scholar
• Executive summary of the GESIDA/National AIDS Plan Consensus Document on Antiretroviral Therapy in Adults Infected by the Human Immunodeficiency Virus (Updated January). AIDS study gropu (GESIDA) of the spanish society of infectious diseases, clinical microbiology, the national AIDS plan. Enferm Infecc Microbiol Clin. 2016;34(7):439–451. 2016
   PubMedGoogle Scholar
• Friedman E, Duffus W. Chronic health conditions in medicare beneficiaries 65 years and older with HIV infection. AIDS. 2016;30(16):2529–2536.
   PubMed Web of Science ®Google Scholar
• Levy ME, Greenberg AE, Hart R, et al. for the DC Cohort Executive Committee. High Burden Metabolic Comorbidities Citywide Cohort HIV Outpatients: Evolving Health Care Needs People Aging with HIV Washington, DC. HIV Med. 2017;18(10):724–735.
   PubMed Web of Science ®Google Scholar
• Gunter J, Callens S, De Wit S, et al. Prevalence of non-infectious comorbidities in the HIV-positive population in Belgium: a multicenter, retrospective study. Acta Clin Belg. 2017;16:1–4.
   Google Scholar
• CDC. Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMRW. 1992;41(RR–17):1–19.
   Google Scholar
• Blanco JR, Caro AM, Pérez-Cachafeiro S, et al. HIV infection and aging. AIDS Rev. 2010;12(4):218–230.
   PubMed Web of Science ®Google Scholar
• Castilla J, Pollán M, López-Abente G. The AIDS epidemic among Spanish drug users: a birth cohort-associated phenomenon. Am J Public Health. 1997;87(5):770–774.
   PubMed Web of Science ®Google Scholar
• Castilla J., de la Fuente L. Evolución del número de personas infectadas por el virus de la inmunodeficiencia humana y de los casos de sida en España: 1980–1998. Med Clin (Barc). 2000;115(3):85–89.
   PubMedGoogle Scholar
• Castilla J, Sobrino P, Lorenzo JM, et al. Situación actual y perspectivas futuras de la epidemio de VIH y sida en España. An Sist Sanit Navar. 2006;29(1):13–25.
   PubMedGoogle Scholar
• Sico JJ, Chang CC, So-Armah K, et al. Veterans aging cohort study. HIV status risk ischemic stroke among men. Neurology. 2015;84:1933–1940.
   PubMed Web of Science ®Google Scholar
• Berenguer J, Rivero A, Jarrín I, et al. Human immunodeficiency Virus/Hepatitis C virus coinfection in Spain: prevalence and patient characteristics. Open Forum Infect Dis. 2016;3(2):ofw059.
   PubMed Web of Science ®Google Scholar
• Serrano-Villar S, Sainz T, Lee SA, et al. HIV-Infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality. PLoS Pathog. 2014;10(5):31004078.
   Web of Science ®Google Scholar
• Nlooto M. Comorbidities of HIV infection and health care seeking behavior among HIV infected patients attending public sector healthcare facilities in KwaZulu-Natal: A cross sectional study. Plos One. 2017;12(2):e0170983.
   PubMed Web of Science ®Google Scholar
• Vance D, Mugavero M, Willig J, et al. Aging with HIV: A cross-sectional study of comorbidity prevalence and clinical characteristics across decades of life. J Assoc Nurses AIDS Care. 2011;22(1):17–25.
   PubMed Web of Science ®Google Scholar
• Shahmanesh M, Schultze A, Burns F, et al.EuroSIDA in EuroCOORD. The cardiovascular risk management for people living with HIV in Europe: how well are we doing? AIDS. 2016;30(16):2505–2518.
   PubMed Web of Science ®Google Scholar
• Friis-Moller N, Ryom L, Smith C, et al. on behalf of the D:A:D study group. Updated prediction model global risk cardiovascular disease HIV-positive persons: data-collection adverse effects Anti-HIV Drugs (D:A:D) study. Eur J Prev Cardiol. 2015;23(2):214–223.
   PubMed Web of Science ®Google Scholar
• Gnjidic D. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community- dwelling older men at risk of different adverse outcomes. J Clin Epidemiol. 2012;65(9):895–989.
   Web of Science ®Google Scholar
• European AIDS Clinical Society. Guidelines Version 9.0 Octubre 2017. Available from: http://www.eacsociety.org/files/guidelines_9.0-english.pdf
   Google Scholar